Latest news
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Q2 Results And Early RM-718 Obesity Data - simplywall.stsimplywall.st · Thu, 06 Aug 2026 22:10:03 GMTThe divide between Eli Lilly and Novo Nordisk is widening after their latest earnings - CNBCCNBC · Thu, 06 Aug 2026 13:45:29 GMTNovo CEO looks to speed up R&D as share drop shows gap with Lilly - ReutersReuters · Wed, 05 Aug 2026 15:33:40 GMTiBio Expands Must-have Cardiometabolic and Obesity Pipeline Investor through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio - Diario ASDiario AS · Wed, 05 Aug 2026 06:42:43 GMTIs Ascletis’ Biologic Obesity Pipeline Altering The Investment Case For Ascletis Pharma (SEHK:1672)? - simplywall.stsimplywall.st · Mon, 03 Aug 2026 17:24:29 GMTVKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress - TradingViewTradingView · Wed, 29 Jul 2026 23:58:14 GMTWhy shareholders are suing Novo Nordisk over next-generation weight-loss drug - CNBCCNBC · Wed, 29 Jul 2026 07:00:00 GMT